Supporting Information for

Two scaffolds from two flips: $(\alpha,\beta)/(\beta,\gamma)$ CH₂/NH "Met-Im" analogues of dTTP

Anastasia P. Kadina,^a Boris A. Kashemirov,^a Keriann Oertell,^b Vinod K. Batra,^c Samuel H. Wilson,^c Myron F. Goodman,^b Charles E. McKenna^a*

^aDepartment of Chemistry, Dana and David Dornsife College of Letters, Arts and Sciences, University of Southern California, University Park Campus, Los Angeles, CA 90089, USA ^bDepartment of Biological Sciences, Dana and David Dornsife College of Letters, Arts and Sciences, University of Southern California, University Park Campus, Los Angeles, CA 90089, USA ^cLaboratory of Structural Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA

Table of Contents

I.	General Information	4
II.	Experimental Procedures and Compound Characterization	5
	Diethyl benzylphosphoramidate (2a)	5
	Dimethyl benzylphosphoramidate $(2b)^3$	6
	Ethyl methylphosphonochloridate ⁴	6
	Benzyl(diethoxyphosphoryl)[ethoxy(methyl)phosphoryl]amine (3a)	7
	Benzyl(dimethoxyphosphoryl)[ethoxy(methyl)phosphoryl]amine (3b)	8
	Dimethyl ({[benzyl(diethoxyphosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (4a)	9
	Diethyl ({[benzyl(dimethoxyphosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (4b)	. 10
	[(2 <i>R</i> ,3 <i>S</i> ,5 <i>R</i>)-3-Hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methyl methyl ({[benzyl(diethoxyphosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (6a)	. 11
	Diethyl ({[benzyl({[(2 <i>R</i> ,3 <i>S</i> ,5 <i>R</i>)-3-hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methoxy}(methoxy)phosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (6b))12
	[(2 <i>R</i> ,3 <i>S</i> ,5 <i>R</i>)-3-Hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methyl methyl ({[(diethoxyphosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (7a)	. 13

Diethyl ({ethoxy[({[(2 <i>R</i> ,3 <i>S</i> ,5 <i>R</i>)-3-hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin l)oxolan-2-yl]methoxy}(methoxy)phosphoryl)amino]phosphoryl}methyl)phosphonate (7b)	1-1- 14
[({[(2 <i>R</i> ,3 <i>S</i> ,5 <i>R</i>)-3-Hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2 l]methyl phosphonato}methyl)phosphinato]amino}phosphonate (TEA/Na salt) [(α , β)-CH ₂ -(β TTP (1a)	- δ,γ)-NH- 15
{[({[($2R,3S,5R$)-3-Hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2 l]methoxy}phosphinato)amino]phosphinato}methyl)phosphonate (TEA salt) [(α,β)-NH-(β,γ) TTP] (1b)	2- -CH ₂ - 15
DNA synthesis, purification, radiolabeling, and annealing	16
DNA synthesis kinetics	16
Trystallization of the Pol β Substrate Complex	17
Data collection and structure determination	
Sable S1. Crystallographic Statistics	19
NMR Spectra of Compounds 1-7	20
igure S1. ¹ H NMR of 2a (CDCl ₃ , 500 MHz)	21
Figure S2. ³¹ P NMR of 2a (CDCl ₃ , 202 MHz)	21
Sigure S3. ¹ H NMR of 2b (CDCl ₃ , 500 MHz)	22
Sigure S4. ³¹ P NMR of 2b (CDCl ₃ , 202 MHz)	22
Figure S5. ¹ H NMR of 3a (CDCl ₃ , 500 MHz)	23
Figure S6. ³¹ P NMR of 3a (CDCl ₃ , 202 MHz)	23
Figure S7. ¹³ C NMR of 3a (CDCl ₃ , 126 MHz)	24
Figure S8. ¹ H NMR of 3b (CDCl ₃ , 500 MHz)	25
Figure S9. ³¹ P NMR of 3b (CDCl ₃ , 202 MHz)	25
Figure S10. ¹³ C NMR of 3b (CDCl ₃ , 126 MHz)	
igure S11. ¹ H NMR of 4a (CDCl ₃ , 500 MHz)	27
Sigure S12. ³¹ P NMR of 4a (CDCl ₃ , 202 MHz)	27
Sigure S13. ¹³ C NMR of 4a (CDCl ₃ , 126 MHz)	
Figure S14. ¹ H - ³¹ P gHMBC NMR of 4a (CDCl ₃ , 500 MHz)	

Figure S15. ¹ H NMR of 4b (CDCl ₃ , 500 MHz)	
Figure S16. ³¹ P NMR of 4b (CDCl ₃ , 202 MHz)	
Figure S17. ¹³ C NMR of 4b (CDCl ₃ , 126 MHz)	
Figure S18. ${}^{1}\text{H} - {}^{31}\text{P}$ gHMBC NMR of 4b (CDCl ₃ , 500 MHz)	
Figure S19. ³¹ P – ¹ H NMR of 4b (CDCl ₃ , 202 MHz)	
Figure S20. ¹ H NMR of 6a (mixture of 4 isomers) (CDCl ₃ , 500 MHz)	
Figure S21. ³¹ P NMR of 6a (mixture of 4 isomers) (CDCl ₃ , 202 MHz)	
Figure S22. ¹ H NMR of 6b (mixture of 4 isomers) (CDCl ₃ , 400 MHz)	
Figure S23. ³¹ P NMR of 6b (mixture of 4 isomers) (CDCl ₃ , 162 MHz)	
Figure S24. ¹ H NMR of 7a (mixture of 4 isomers) (CD ₃ OD, 500 MHz)	
Figure S25. ³¹ P NMR of 7a (mixture of 4 isomers) (CD ₃ OD, 202 MHz)	
Figure S26. ¹ H NMR of 7b (mixture of 4 isomers) (CD ₃ OD, 400 MHz)	
Figure S27. ³¹ P NMR of 7b (mixture of 4 isomers) (CD ₃ OD, 162 MHz)	
Figure S28. ¹ H NMR of α-1a (D ₂ O, 500 MHz)	
Figure S29. ³¹ P NMR of α-1a (D ₂ O, 202 MHz)	
Figure S30. ¹ H NMR of 1a (D ₂ O, 500 MHz)	
Figure S31. ³¹ P NMR of 1a (D ₂ O, 202 MHz)	
Figure S32. ¹ H NMR of 1b (D ₂ O, 400 MHz)	
Figure S33. ³¹ P NMR of 1b (D ₂ O, 162 MHz)	
IV. References	

I. General Information

All the reagents and solvents were purchased from VWR, Sigma-Aldrich, or Alfa Aesar and used without further purification, unless noted otherwise. ¹H, ¹³C and ³¹P NMR spectra were obtained on Varian 400-MR or VNMRS-500 spectrometers. ¹³C and ³¹P NMR spectra were protondecoupled unless stated otherwise. All chemical shifts (δ) are reported in parts per million (ppm) relative to residual CH₃OH in CD₃OD (δ 3.34, ¹H NMR), CHCl₃ in CDCl₃ (δ 7.26, ¹H NMR), HDO in D₂O (δ 4.80, ¹H NMR), external 85% H₃PO₄ (δ 0.00, ³¹P NMR) or internal CDCl₃ (δ 77.00, ¹³C NMR). The concentration of the NMR samples was 2 - 15 mg/ml. 1D and 2D NMR spectra processing was performed with MestReNova 9.0.0. Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad resonance. Preparative HPLC was performed using a Varian ProStar equipped with a Shimadzu SPD-10A UV detector (0.5 mm path length) with detection at 260 nm. Strong Anion Exchange (SAX) HPLC was performed using a Macherey Nagel 21.4 mm × 250 mm SP15/25 Nucleogel column, C-18 HPLC was performed using a Phenomenex Luna 5u C18 (21.20 mm × 250 mm). Mass spectrometry was performed on a Finnigan LCQ Deca XP Max mass spectrometer equipped with an ESI source in the negative ion mode. Microwave-assisted synthesis was performed using a Milestone Ethos Synth Microwave Labstation. Compound IUPAC names were assigned with the assistance of MarvinSketch 6.1.5. The molar yields of the final products were determined by UV absorbance using the extinction coefficient of dTTP in phosphate buffer at pH 7.0 at 260 nm, $\varepsilon =$ 9600.¹

II. Experimental Procedures and Compound Characterization



Diethyl benzylphosphoramidate (2a)

Compound **2a** was previously made by the reaction of diethyl phosphite and benzylamine in the presence of hydrogen peroxide and a catalytic amount of I_2 ,² however, we found that it could be conveniently obtained by adapting the procedure of Glidewell.³

Benzylamine (2.14 g, 0.02 mol) was added to a solution of diethylphosphite (1.38 g, 0.01 mol) in CCl₄ (20 mL). A white precipitate appeared immediately, and the reaction mixture was stirred overnight at r. t. The white precipitate was filtered, washed with CH₂Cl₂, and volatiles were removed from the combined filtrate and washings by rotary evaporation (water pump). The residue was dried under vacuum at r.t. (<1 mm), giving 2.4 g of the product **2a** as a colorless oil (99%). ¹H NMR (500 MHz, CDCl₃): δ 7.36-7.27 (m, 5H, C₆H₅), 4.13-3.99 (m, 6H, CH₂C₆H₅ and CH₂CH₃), 2.89 (br, 1H, NH), 1.31 (t, *J* = 7.1 Hz, 6H, 2 × OCH₂CH₃). ³¹P NMR (202 MHz, CDCl₃): δ 8.36. Lit. data:^{2 1}H NMR (400 MHz, CDCl₃): δ 7.33-7.25 (m, 5H, C₆H₅), 4.11-3.98 (m, 6H, CH₂C₆H₅ and CH₂CH₃), 3.22 (br, 1H, NH), 1.29 (t, *J* = 7.1 Hz, 6H, 2 × OCH₂CH₃). ³¹P NMR (202 MHz, CDCl₃): δ 8.50.



Dimethyl benzylphosphoramidate (2b)³

Benzylamine (3.3 g, 0.03 mol) was added to a solution of dimethyl phosphite (1.65 g, 0.015 mol) in CCl₄ (20 mL). A white precipitate appeared immediately, and the reaction mixture was stirred overnight at r. t. The white precipitate was filtered, washed with CH₂Cl₂, and volatiles were removed from the combined filtrate by rotary evaporation (water pump). The residue was dried under vacuum at r. t. (<1 mm), giving 2.98 g of the product **2b** as a colorless oil that crystallized in the refrigerator (~ -20°C) but remelted on rewarming to r.t. (92%). ¹H NMR (500 MHz, CDCl₃): δ 7.36-7.28 (m, 5H, C₆H₅), 4.10 (dd, *J* = 9.7 Hz, *J* = 7.0 Hz, 2H, CH₂C₆H₅), 3.72 (d, *J* = 10.7 Hz, 6H, 2 × OCH₃), 2.88 (br, 1H, NH). ³¹P NMR (202 MHz, CDCl₃): δ 10.93. Lit. data: ³ ¹H NMR (60 MHz, CCl₄) δ 7.30 (s, 5H), 5.38 (dt, *J* = 11 Hz, *J* = 6 Hz, 1H), 3.98 (dd, *J* = 11 Hz, *J* = 6 Hz, 2H), 3.58 (d, *J* = 11 Hz, 6H). ³¹P NMR (32 MHz, CCl₄): δ 11.7.



Ethyl methylphosphonochloridate⁴

Oxalyl chloride (1.27 g, 0.01 mol) was added in one portion to a solution of diethyl methylphosphonate (1.52 g, 0.01 mol) in 15 mL of dry CH_2Cl_2 . The reaction mixture was stirred for 16 h at r.t. The solvent was removed by evaporation, and the residue was distilled in vacuo, yielding 1.03 g of the product as a colorless liquid (72%): bp 75-76 °C/14 mmHg (lit. bp 62-64 °C/8 mmHg).⁴ ¹H NMR (500 MHz, CDCl₃): δ 4.32 (m, 1H, CH_2CH_3), 4.23 (m, 1H, CH_2CH_3),

1.97 (d, *J* = 17.5 Hz, 3H, P-C*H*₃), 1.40 (t, *J* = 7.1 Hz, 3H, CH₂C*H*₃). ³¹P NMR (202 MHz, CDCl₃): δ 40.06. Lit. data:⁴ ¹H NMR (300/500 MHz, CDCl₃): δ 4.41-4.17 (m, 2H, OC*H*₂), 1.98 (d, *J* = 18 Hz, 3H, P-C*H*₃), 1.41 (t, *J* = 7 Hz, 3H, C*H*₃).

Benzyl(diethoxyphosphoryl)[ethoxy(methyl)phosphoryl]amine (3a)

To a suspension of t-BuOK (800 mg, 7.16 mmol) in 15 mL of dry toluene was slowly added a solution of compound 2a (1.16 g, 4.77 mmol) in 5 mL of dry toluene. The reaction mixture was stirred for 5 min, and a solution of ethyl methylphosphonochloridate (1.02 g, 7.16 mmol) in 2 mL of dry toluene was added. The reaction mixture was stirred overnight, and then quenched by addition of a saturated aqueous solution of NH₄Cl. The product was extracted into EtOAc (3 \times 15 mL), and the combined organic layers were washed with brine, then dried over Na₂SO₄. After evaporation of the solvent, the residual product was purified by column chromatography on silica gel (EtOAc:Hexanes (3:1) \rightarrow EtOAc), giving 1.176 g of **3a** as a colorless oil (71%). ¹H NMR (500 MHz, CDCl₃): δ 7.49-7.21 (m, 5H, CH₂C₆H₅), 4.67-4.42 (m, 2H, CH₂C₆H₅), 4.11-3.67 (m, 6H, $3 \times OCH_2CH_3$), 1.71 (d, $J_{HP} = 17.5$ Hz, 3H, PCH₃), 1.27 (t, J = 7.1 Hz, 3H, OCH₂CH₃), 1.22 (t, J = 7.1 Hz, 3H, OCH₂CH₃), 1.16 (t, J = 7.1 Hz, 3H, OCH₂CH₃). ³¹P NMR (202 MHz, CDCl₃): δ 32.99 (d, J = 18.1 Hz, 1P, CH₃(EtO)P(O)), 3.55 (d, J = 18.1 Hz, 1P, P(O)(OEt)₂). ¹³C NMR (126 MHz, CDCl₃): δ 138.6, 128.9, 128.1, 127.4, 63.02 (d, J_{CP} = 5.9 Hz), 62.98 (d, J_{CP} = 5.1 Hz), 60.9 (d, J_{CP} = 6.7 Hz), 49.0, 16.1 (d, J_{CP} = 7.1 Hz), 15.9 (d, J_{CP} = 7.2 Hz), 15.8 (d, J_{CP} = 7.5 Hz), 15.2 (d, $J_{CP} = 134$ Hz). MS (m/z): calcd for $C_{14}H_{25}NNaO_5P_2^+$ [M+Na]⁺: 372.1, found: 372.4 $[M+Na]^+$.

 $\begin{array}{c} O & O \\ EtO & H \\ H_3C & N \\ \end{array} \begin{array}{c} O & O \\ H_2 & OMe \\ OMe \\ Bn \\ \mathbf{3b} \end{array}$

Benzyl(dimethoxyphosphoryl)[ethoxy(methyl)phosphoryl]amine (3b)

To a suspension of t-BuOK (400 mg, 3.6 mmol) in 7 mL of dry toluene was slowly added a solution of compound **2b** (645 mg, 3 mmol) in 5 mL of dry toluene. The reaction mixture was stirred for 5 min, and a solution of ethyl methylphosphonochloridate (442 mg, 3.1 mmol) in 3 mL of dry toluene was added. The mixture was stirred overnight, and then guenched by addition of a saturated aqueous solution of NH₄Cl. The product was extracted into EtOAc (3×15 mL), and the combined organic layers were washed with brine, then dried over Na₂SO₄. After evaporation of the solvent, the residual product was purified by column chromatography on silica gel (EtOAc \rightarrow 3% MeOH in EtOAc), giving 0.88 g of **3b** as a colorless oil (91%). ¹H NMR (500 MHz, CDCl₃): δ 7.52-7.25 (m, 5H, CH₂C₆H₅), 4.69-4.43 (m, 2H, CH₂C₆H₅), 4.15-4.07 (m, 1H, OCH_2CH_3), 3.97-3.89 (m, 1H, OCH_2CH_3), 3.64 (d, J = 11.4 Hz, 3H, OCH_3), 3.53 (d, J = 11.4Hz, 3H, OCH₃), 1.71 (d, J = 17.4 Hz, 3H, CH₃P(O)), 1.30 (t, J = 7.1 Hz, 3H, OCH₂CH₃). ³¹P NMR (202 MHz, CDCl₃): δ 32.89 (d, J = 18.2 Hz, 1P, H₃C(EtO)P(O)), 6.54 (d, J = 18.2 Hz, 1P, $(MeO)_2 P(O)$). ¹³C NMR (101 MHz, CDCl₃): δ 138.4, 128.9, 128.2, 127.6, 61.1 (d, $J_{CP} = 6.5$ Hz), 53.5 (d, J_{CP} = 5.4 Hz), 53.4 (d, J_{CP} = 5.4 Hz), 49.1, 16.1 (d, J_{CP} = 7.6 Hz), 15.1 (d, J_{CP} = 134 Hz). MS (m/z): calcd for C₁₂H₂₂NO₅P₂⁺: 322.1 [M+H]⁺, found: 322.4 [M+H]⁺.



Dimethyl ({[benzyl(diethoxyphosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (4a)

A solution of BuLi in hexane (2.8 mL, 4.4 mmol) was added to a dry flask under N₂ and cooled to -20 °C. Then freshly distilled diisopropylamine (b.p. = 82-84°C) (655 μ L, 4.68 mmol) in 3 mL of dry THF was added. After stirring for 5 min, the reaction mixture was cooled to -78 °C, and a solution of **3b** (680 mg, 2.12 mmol) in 3 mL of dry THF was added.

The reaction mixture was stirred for 1.5 min at -78 °C, and a solution of diethyl chlorophosphate (439 mg, 2.54 mmol) was slowly added, after which the reaction mixture was allowed to warm up gradually to r.t. and left to stand overnight.

After cooling to 0 °C, the reaction mixture was quenched with saturated NH₄Cl, and the product extracted into EtOAc (3 × 15 mL). The combined organic fractions were washed with brine and dried with Na₂SO₄. The product **4a** was purified by column chromatography on silica gel (2% \rightarrow 5% MeOH in EtOAc) and isolated as a colorless oil (800 mg, 83%). ¹H NMR (500 MHz, CDCl₃): δ 7.52-7.23 (m, 5H, CH₂C₆H₅), 4.76-4.39 (m, 2H, CH₂C₆H₅), 4.18-4.09 (m, 2H, OCH₂CH₃), 4.02-3.95 (m, 3H, OCH₂CH₃), 3.88-3.82 (m, 1H, OCH₂CH₃), 3.84 (d, *J* = 11.3 Hz, 3H, OCH₃), 3.79 (d, *J* = 11.3 Hz, 3H, OCH₃), 3.06-2.77 (m, 2H, PCH₂P), 1.28 (t, *J* = 7.0 Hz, 6H, OCH₂CH₃), 1.15 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃). ³¹P NMR (202 MHz, CDCl₃): δ 23.22 (dd, *J* = 19.8, 4.3 Hz, 1P, PCH₂PNP), 22.70 (d, *J* = 4.3 Hz, 1P, PCH₂PNP), 2.79 (d, *J* = 19.8 Hz, 1P, PCH₂PNP). ¹³C NMR (126 MHz, CDCl₃): δ 138.3, 129.3, 128.1, 127.6, 63.5 (d, *J_{CP}* = 5.2 Hz), 63.1 (d, *J_{CP}* = 5.7 Hz), 62.0 (d, *J_{CP}* = 6.8 Hz), 53.2 (d, *J_{CP}* = 6.1 Hz), 52.9 (d, *J_{CP}* = 6.1 Hz), 49.9,

27.2 (dd, J_{CP} = 135.1 Hz, J_{CP} = 127.3 Hz), 16.1 (d, J_{CP} = 7.3 Hz), 16.0 (d, J_{CP} = 7.6 Hz), 15.8 (J_{CP} = 7.6 Hz).



Diethyl ({[benzyl(dimethoxyphosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (4b)

A solution of butyllithium in hexane (3.75 mL, 6 mmol) was added to a dry flask under N₂ and cooled to -20 °C. Then freshly distilled diisopropylamine (924 μ L, 6.6 mmol) in 3 mL of dry THF was added. After stirring for 5 min, the reaction mixture was cooled to -78 °C, and a solution of **3a** (1.047 g, 3 mmol) in 6 mL of dry THF was added.

The resulting solution was stirred for 1.5 min at -78 °C, and a solution of dimethyl chlorophosphate (520 mg, 3.6 mmol) in dry THF (2 mL) was slowly added. The reaction mixture was allowed to warm up gradually to r.t. and left to stand overnight.

After cooling to 0 °C, the reaction mixture was quenched with a saturated aqueous solution of NH₄Cl and extracted into EtOAc (3 × 15 mL). The combined organic fractions were washed with brine and dried with Na₂SO₄. The product **4b** was purified by column chromatography on silica gel (EtOAc \rightarrow 2% MeOH in EtOAc) and isolated as a colorless oil (805 mg, 59%). ¹H NMR (500 MHz, CDCl₃): δ 7.52-7.25 (m, 5H, CH₂C₆H₅), 4.76-4.37 (m, 2H, CH₂C₆H₅), 4.26-3.93 (m, 6H, 3 × OCH₂CH₃), 3.70 (d, *J* = 11.4 Hz, 3H, OCH₃), 3.54 (d, *J* = 11.5 Hz, 3H, OCH₃), 3.02-2.72 (m, 2H, PCH₂P), 1.35 (t, *J* = 7.2 Hz, 3H, OCH₂CH₃), 1.34 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 1.27 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃). ³¹P NMR (202 MHz, CDCl₃): δ 23.38 (dd, *J* = 19.8, 4.0 Hz,

1P, PCH₂*P*NP), 19.65 (d, J = 4.0 Hz, 1P, *P*CH₂PNP), 5.76 (d, J = 19.8 Hz, 1P, PCH₂PN*P*). ¹³C NMR (126 MHz, CDCl₃): δ 138.2, 129.3, 128.2, 127.6, 62.7 (d, J = 6.3 Hz), 62.3 (d, J = 6.2 Hz), 62.0 (d, J = 6.7 Hz), 53.8 (d, J = 5.3 Hz), 53.4 (d, J = 5.7 Hz), 49.9, 28.0 (dd, $J_{CP} = 134.7$ Hz, $J_{CP} = 127.0$ Hz), 16.4 (d, $J_{CP} = 6.4$ Hz), 16.3 (d, $J_{CP} = 6.4$ Hz), 16.1 ($J_{CP} = 7.1$ Hz). MS (*m*/*z*): calcd for C₁₆H₃₁NO₈P₃⁺ 458.1 [M+H]⁺, found: 458.5 [M+H]⁺.



[(2*R*,3*S*,5*R*)-3-Hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2yl]methyl methyl

({[benzyl(diethoxyphosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (6a)

A solution of **4a** (320 mg, 0.7 mmol) and 3 mL of triethylamine in 3 mL of acetonitrile was refluxed for 12 h. The reaction progress was monitored by ³¹P NMR. After completion, solvents were removed under reduced pressure and the residue dried in vacuo. The resulting oil was passed through a column of DOWEX H⁺, the acidic fractions were collected and the solvent removed under reduced pressure, yielding 279 mg (90%) of the corresponding acid **5a** as a colorless oil, which was used without further purification.

Acid **5a** (279 mg, 0.63 mmol), thymidine (153 mg, 0.63 mmol), and PPh₃ (247 mg, 0.945 mmol) were co-evaporated with 5 mL of dry DMF 3 times, and then dissolved in 2 mL of dry DMF. DIAD (186 μ L, 0.945 mmol) was added dropwise and the resulting mixture allowed to stand at r.t.

After 3 d, the solvent was removed under reduced pressure and the residue dissolved in EtOAc and washed with 10 mL of 10% NaHCO₃. The aqueous layer was extracted with EtOAc (3×15

mL), and the combined organic layers were washed with brine and dried over Na₂SO₄. Product **6a** was isolated by column chromatography (EtOAc \rightarrow 10% MeOH in EtOAc) as a mixture of 4 isomers (247 mg, 59%). The ¹H and ³¹P NMR spectra are presented in **Figs. S20** and **S21**, respectively. ¹H NMR (500 MHz, CDCl₃): δ 8.73-8.71 (1H, NH), 7.52-7.24 (6H, CH₂C₆H₅, CH-T), 6.43-6.16 (1H, H-1'), 4.72-3.78 (15H, CH₂C₆H₅, 3 × OCH₂CH₃, H-5', H-4', H-3', OCH₃), 3.43-2.68 (2H, PCH₂P), 2.49-2.19 (2H, H-2'), 1.94-1.90 (3H, CH₃-T), 1.41-1.15 (9H, 3 × OCH₂CH₃). ³¹P NMR (202 MHz, CDCl₃): δ 23.80-19.84 (2P, P_β and P_α), 2.64-2.26 (1P, P_γ).



Diethyl ({[benzyl({[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-

tetrahydropyrimidin-1-yl)oxolan-2-

yl]methoxy}(methoxy)phosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (6b)

A solution of **4b** (220 mg, 0.48 mmol) in 2 mL of MeCN and 2 mL of TEA was refluxed for 3 h. The reaction progress was monitored by ³¹P NMR. After completion, solvents were removed and the residue was dissolved in water and extracted with EtOAc (10 ml). The aqueous layer was evaporated at reduced pressure and the residue dried in vacuo. It was then dissolved in MeOH (5mL) and stirred with DOWEX H⁺ (300 mg) overnight. After removal of the solvent at reduced pressure, 155 mg (73%) of the acid **5b** was obtained as a colorless oil, which was used without further purification.

Thymidine (90 mg, 0.35 mmol), acid **5b** (155 mg, 0.35 mmol), and PPh₃ (137 mg, 0.525 mmol) were co-evaporated with 3 mL of dry DMF 3 times, and then dissolved in 2 mL of dry DMF. To

this solution, DIAD (103 μ L, 0.525 mmol) was slowly added and the reaction mixture was allowed to stand at r.t.

After 4 days, the solvent was evaporated and the residue was dissolved in EtOAc and washed with 10 mL of 10% NaHCO₃. The aqueous layer was extracted with EtOAc (3×15 mL), and the combined organic layers were washed with brine, then dried over Na₂SO₄. Product **6b** was isolated by column chromatography (EtOAc \rightarrow 6% MeOH in EtOAc) as a mixture of 4 isomers (72 mg, 31%). The ¹H and ³¹P NMR spectra are presented in **Fig. S22** and **S23**, respectively. ¹H NMR (400 MHz, CDCl₃): δ 9.32-9.28 (1H, N*H*), 7.50-7.24 (6H, CH₂C₆*H₅*, C*H*-T), 6.29-6.15 (1H, H-1'), 4.82-3.71 (12H, C*H*₂C₆H₅, 3 × OC*H*₂CH₃, H-5', H-4', H-3'), 3.54-3.47 (3H, OC*H*₃), 3.26-2.54 (2H, PC*H*₂P), 2.40-2.18 (2H, H-2'), 1.92-1.87 (3H, C*H*₃-T), 1.41-1.23 (9H, 3 × OCH₂C*H*₃). ³¹P NMR (162 MHz, CDCl₃): δ 23.28-22.83 (1P, P_β), 19.53-19.27 (1P, P_γ), 5.65-4.79 (1P, P_q).

[(2*R*,3*S*,5*R*)-3-Hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2yl]methyl methyl ({[(diethoxyphosphoryl)amino](ethoxy)phosphoryl}methyl)phosphonate (7a)

Compound **6a** (247 mg, 0.37 mmol) was dissolved in methanol (7 mL), and 15 mg (6 wt. %) of Pd(OH)₂/C was added. The reaction mixture was stirred under 1 atm H₂ for 20 h, then filtered through a celite pad, and the volatiles evaporated to yield 206 mg of **7a** as a mixture of 4 isomers as a colorless oil (97%). ¹H NMR (500 MHz, CD₃OD): δ 7.59-7.56 (1H, CH-T), 6.29-6.26 (1H, H-1'), 4.47-4.04 (10H, 3 × OCH₂CH₃, H-5', H-4', H-3'), 3.83-3.79 (3H, OCH₃), 3.04-2.84 (2H,

PC H_2 P), 2.29-2.25 (2H, H-2'), 1.91-1.90 (3H, C H_3 -T), 1.37-1.33 (9H, 3 × OCH₂C H_3). ³¹P NMR (202 MHz, CD₃OD): δ 22.89-21.95 (1P, P_a), 18.76-18.34 (1P, P_β), -0.22-(-0.31) (1P, P_γ). MS (*m/z*): calcd for C₁₈H₃₃N₃O₁₂P₃⁻ 576.1 [M-H]⁻, found: 576.1 [M-H]⁻.



Diethyl ({ethoxy[({[(2*R*,3*S*,5*R*)-3-hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4tetrahydropyrimidin-1-yl)oxolan-2-

yl]methoxy}(methoxy)phosphoryl)amino]phosphoryl}methyl)phosphonate (7b)

Compound **6b** (72 mg, 0.108 mmol) was dissolved in methanol (3 mL), and 7 mg (10 wt. %) of Pd(OH)₂/C was added. The reaction mixture was stirred under 1 atm H₂ for 4 h, then filtered through a celite pad. Volatiles were evaporated from the filtrate, yielding 60 mg of **7b** as a mixture of 4 isomers as a colorless oil (96%). ¹H NMR (400 MHz, CD₃OD): δ 7.58-7.56 (1H, C*H*-T), 6.30-6.26 (1H, H-1'), 4.48-4.03 (10H, 3 × OC*H*₂CH₃, H-5', H-4', H-3'), 3.86-3.81 (3H, OC*H*₃), 2.95-2.74 (2H, PC*H*₂P), 2.27-2.24 (2H, H-2'), 1.91-1.90 (3H, C*H*₃-T), 1.38-1.32 (9H, 3 × OCH₂C*H*₃). ³¹P NMR (162 MHz, CD₃OD): δ 19.75-19.66 (1P, P_β), 18.70-18.55 (1P, P_γ), 1.91-1.59 (1P, P_g).



{[({[(2R,3S,5R)-3-Hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methyl phosphonato}methyl)phosphinato]amino}phosphonate (TEA/Na salt) [(α,β)-CH₂-(β,γ)-NH-dTTP (1a)

A mixture of **7a** (10 mg, 17 µmol), dry DMF (20 µL) and BTMS (200 µL, 1.52 mmol) was microwaved at 40 °C for 30 min. The reaction mixture was allowed to cool to r. t., volatiles were removed in vacuo, and the residue was treated with 1 mL of Et₃N-MeOH (1:5). The product was purified by two-stage preparative HPLC: first, on a SAX column (0-0.5 M TEAB gradient in 20 min); then, on a C-18 column (0.1 M TEAB:5% MeCN, pH = 6.9). The fractions containing **1a** (identified by MS) were collected and combined, and evaporated yielding the TEA salt of compound **1a**. The solution of **1a** in water was treated with DOWEX Na⁺ (20 mg) and lyophilized again to yield Na-TEA salt of compound **1a** (2.2 mg, 27%). ¹H NMR (500 MHz, D₂O): δ 7.62 (s, 1H, CH-T), 6.39 (t, *J* = 7.0 Hz, 1H, H-1'), 4.64-4.62 (m, 1H, H-3'), 4.17-4.07 (m, 3H, H-4', H-5'), 2.40 (t, *J* = 19.5 Hz, 2H, PCH₂P), 2.39-2.30 (m, 2H, H-2'), 1.92 (s, 3H, CH₃-T). ³¹P NMR (202 MHz, D₂O): δ 19.89 (d, *J* = 9.8 Hz, 1P, P_a), 12.28 (d, *J* = 9.8 Hz, 1P, P_β), -0.31 (s, 1P, P_γ). MS (*m/z*): calcd for C₁₁H₁₉N₃O₁₂P₃⁻⁴ 478.0 [M-H]⁻, found: 478.1 [M-H]⁻.

({[({[(2*R*,3*S*,5*R*)-3-Hydroxy-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methoxy}phosphinato)amino]phosphinato}methyl)phosphonate (TEA salt) [(α,β)-NH-(β,γ)-CH₂-dTTP] (1b)

A mixture of **7b** (5.0 mg, 8.7 μ mol), dry DMF (100 μ L) and BTMS (100 μ L, 760 μ mol) was microwaved at 40 °C for 8 min. The reaction mixture was cooled to r.t., all volatiles removed in

vacuo, and 1 mL of Et₃N-MeOH (1:5) added. The crude product was purified by two-stage preparative HPLC: first, on a SAX column (0-0.5 M TEAB gradient over 20 min); second, on a C-18 (0.1 M TEAB:5% MeCN, pH = 7.0). The fractions containing **1b** (identified by MS) were collected and combined, and then lyophilized to dryness to provide a TEA salt of compound **1b** (1.9 mg, 46%). ¹H NMR (400 MHz, D₂O): δ 7.71 (s, 1H, CH-T), 6.38 (t, *J* = 6.9 Hz, 1H, H-1'), 4.68-4.65 (m, 1H, H-3'), 4.19-4.08 (m, 3H, H-4', H-5'), 2.44-2.32 (m, 2H, H-2'), 2.08 (t, *J* = 19.2 Hz, 2H, PCH₂P), 1.93 (d, *J* = 1.1 Hz, 3H, CH₃-T). ³¹P NMR (162 MHz, D₂O): δ 15.32 (dd, *J* = 8.3, *J* = 3.9 Hz, 1P, P_{\beta}), 12.30 (d, *J* = 8.3 Hz, 1P, P_{\beta}), 0.68 (d, *J* = 3.9, 1P, P_{\alpha}). MS (*m/z*): calcd for C₁₁H₁₉N₃O₁₂P₃⁻ 478.0 [M-H]⁻, found: 478.1 [M-H]⁻.

DNA synthesis, purification, radiolabeling, and annealing

Primer (5'-TAT TAC CGC GCT GAT GCG C), template, (5'-GCG TTG TTC CGA CAG CGC ATC AGC GCG GTA ATA), and 5'-phosphorylated downstream (5'-GTC GGA ACA ACG C) oligomers were synthesized on a solid phase DNA synthesizer and purified by 16% denaturing polyacrylamide gel electrophoresis, followed by desalting using oligonucleotide purification cartridges. 1 mol equiv primer was 5'-end labeled with 0.4 U/ μ L T4 polynucleotide kinase and 0.7 mol equiv [γ -³²P]ATP with the supplied buffer at 37 °C for 30 minutes, followed by heat inactivation at 95 °C for 10 minutes. The primer was annealed by mixing with 1.2 mol equiv template and 1.5 mol equiv downstream oligomers. The mixture was heated to 95 °C and cooled slowly to room temperature. The reaction buffer consisted of 50 mM Tris-Cl, 20 mM KCl, 20 mM NaCl, 10 mM MgCl2, 1 mM DTT, and 6% glycerol at pH 8.0, 37 °C.

DNA synthesis kinetics

Radiolabeled 1 nt gapped DNA (100 nM) was incubated with pol β (600 nM) in reaction buffer (2x mixture) for 3 minutes at 37 °C. Equal volumes of the DNA/pol β mixture and a 2x solution

of the **1a/1b** at different concentrations and dTTP at 0.2 μ M in reaction buffer were combined and incubated at 37 °C. After the appropriate reaction time, an aliquot of the reaction mixture was quenched with 0.5 M EDTA at pH 8.0. Reaction products were separated by 20% denaturing polyacrylamide gel electrophoresis (39 cm x 33 cm x 0.4 mm). Dehydrated gels were exposed to a phosphor screen and detected by phosphorescence emission.

For each set of reactions, the percentage of primer extended is plotted versus time, and the data for each concentration of analog is fit to the first order exponential $y = a(1-e^{-kt})$, where a is the maximum percent of primer extension and k is the observed rate constant. The observed rate constant (k_{obs}) is then plotted versus the corresponding inhibitor concentration and the data fit to the hyperbolic decay equation $k_{obs} = k_{pol} \times K_i / (K_i + [inhibitor])$ to give the K_i parameter.

Crystallization of the Pol β Substrate Complex

Binary complex crystals of human pol β with a dideoxy-terminated primer in a 1-nucleotide gapped DNA were grown as described previously.⁵ Briefly, the sequence of the template strand (16-mer) was 5'-CCGACAGCGCATCAGC-3'. The primer strand (9-mer) sequence was 5'-GCTGATGCG-3'. The downstream oligonucleotide (5-mer) was 5'-phosphorylated, and the sequence was 5'-GTCGG-3'. These oligonuleotides were annealed in a ratio of 1:1:1 by heating at 90 °C for 10 minutes and cooling to 4 °C (1 °C/min) using a PCR thermocycler, resulting in a 2-nucleotide gapped duplex DNA. These annealed oligonucleotides were further incubated with pol β in a solution containing dideoxyCTP to create a dideoxyCMP-terminated primer. This pol β -DNA binary complex was crystallized by sitting-drop vapor diffusion at 18 °C by mixing 2 µl of the complex with 2 µl of crystallization buffer. The crystallization buffer consisted of 16% PEG-3350, 350 mM sodium acetate, and 50 mM imidazole, pH 7.5. Crystals grew in approximately 2-4 days after seeding. The ternary complexes were obtained by soaking crystals of the binary (one nucleotide gapped DNA) complex in artificial mother liquor containing 50 mM MgCl₂, 20% PEG-3350, 12% ethylene glycol, and 4 mM (α , β)-CH₂-(β , γ)-NH-dTTP or (α , β)-NH-(β , γ)-CH₂-dTTP

for 1-2 hours. The crystals were flash-frozen in a liquid nitrogen stream. Diffraction quality data were then collected for the ternary complex crystals as described below.

Data collection and structure determination

Data were collected at 100 °K on a CCD detector system mounted on a MiraMax[®]-007HF (Rigaku Corporation) rotating anode generator. Data were integrated and reduced with HKL2000 software.⁶ All crystals belong to the space group $P2_1$. The ternary complex structures were solved by molecular replacement using 2FMP⁵ as a reference model. The structure was refined using PHENIX and manual model building using Coot. The crystallographic statistics are reported in Table S1.

Structure factors and the coordinates for the pol β complexes with (α,β) -CH₂- (β,γ) -NH-dTTP and (α,β) -NH- (β,γ) - CH₂-dTTP have been deposited with Protein Data Bank with accession codes 4RT2 and 4RT3, respectively.

Table S1. Crystallographic Statistics

	(α,β) -CH ₂ - (β,γ) -NH-dTTP	(α,β)-NH-(β,γ)-CH ₂ - dTTP
PDB Code	4RT2	4RT3
Data Collection		
Space Group	P2 ₁	$P2_1$
a (Å)	50.7	50.6
b (Å)	79.9	79.4
c (Å)	55.3	55.3
β (°)	107.5	107.3
d _{min} (Å)	1.92	1.92
R_{merge} (%) ^{a, b}	0.084 (0.493)	0.079 (0.479)
Completeness (%)	94.0 (67.4)	89.8 (48)
Unique Reflections	30067 (2142)	28973 (1547)
Total Reflections	106757	96986
I/s	13.8 (2.0)	16.6 (1.9)
Refinement		
r.m.s. deviations		
Bond lengths (Å)	0.007	0.008
Bond angles (°)	1.020	1.040
R_{work} (%) ^c	17.6	18.0
R_{free} (%)	21.1	22.6
Average B Factors (Å)		
Protein	27.4	33.6
DNA	34.4	40.5
Analog	18.7	21.8
Ramachandaran Analysis		
Favored	98.5	98.5
Allowed	100	100

^a R_{merge} =100 x $\Sigma_h \Sigma_i |I_{h,i}$ - $I_h| \Sigma_h \Sigma_i |I_{h,j}$, where I_h is the mean intensity of symmetry related reflections $I_{h,j}$. ^bNumbers in the parentheses refer to the highest resolution shell of data (10%).

 $\label{eq:rescaled} {}^{c}R_{work} = 100 \ x \ \Sigma \ |F_{obs}| \text{-} |F_{calc}| / \Sigma |F_{obs}|.$

III. NMR Spectra of Compounds 1-7





S22



Figure S6. ³¹P NMR of 3a (CDCl₃, 202 MHz)





Figure S9. ³¹P NMR of 3b (CDCl₃, 202 MHz)





Figure S12. ³¹P NMR of **4a** (CDCl₃, 202 MHz)



Figure S14. ¹H - ³¹P gHMBC NMR of 4a (CDCl₃, 500 MHz)



Figure S16. ³¹P NMR of 4b (CDCl₃, 202 MHz)



Figure S18. $^{1}H - ^{31}P$ gHMBC NMR of 4b (CDCl₃, 500 MHz)



Figure S19. ³¹P – ¹H NMR of **4b** (CDCl₃, 202 MHz)



S32



Figure S23. ³¹P NMR of 6b (mixture of 4 isomers) (CDCl₃, 162 MHz)







S36



Figure S31. ³¹P NMR of 1a (D₂O, 202 MHz)



Figure S33. ³¹P NMR of **1b** (D₂O, 162 MHz)

IV. References

1. R. M. C. Dawson, D. C. Elliott, W. H. Elliott, K. M. Jones. *Data for Biochemical Research, third ed.*; Clarendon: Oxford, England, 1986.

2. J. Dhineshkumar, K. R. Prabhu. Org. Lett., 2013, 15, 6062-6065.

3. C. Glidewell and P. J. Pogorzelec, J. Chem. Educ., 1980, 57, 740-741.

4. L. Briseno-Roa, J. Hill, S. Notman, D. Sellers, A. P. Smith, C. M. Timperley, J. Wetherell, N. H. Williams, G. R. Williams, A. R. Fersht and A. D. Griffiths, *J. Med. Chem.*, 2006, **49**, 246-255.

5. V. K. Batra, W. A. Beard, D. D. Shock, J. M. Krahn, L. C. Pedersen, S. H. Wilson, *Structure*, 2006, 14, 757-766.

6. Z. Otwinowski, W. Minor, Methods Enzymol., 1997, 276, 307-326.